Form F-3 - Registration statement by foreign private issuers:
SEC Accession No. 0001213900-25-039303
Filing Date
2025-05-02
Accepted
2025-05-02 17:11:47
Documents
11

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea0240501-f3_enlivex.htm F-3 447185
2 OPINION OF FISCHER (FBC & CO.) ea024050101ex5-1_enlivex.htm EX-5.1 22412
3 OPINION OF GREENBERG TRAURIG, P.A. ea024050101ex5-2_enlivex.htm EX-5.2 25431
4 CONSENT OF YAREL + PARTNERS, INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTING ea024050101ex23-1_enlivex.htm EX-23.1 2725
5 FILING FEE TABLE ea024050101ex-fee_enlivex.htm EX-FILING FEES 111078
6 GRAPHIC image_002.jpg GRAPHIC 5901
7 GRAPHIC ex5-1_001.jpg GRAPHIC 24879
8 GRAPHIC ex5-2_001.jpg GRAPHIC 3433
9 GRAPHIC ex23-1_001.jpg GRAPHIC 2716
10 GRAPHIC ex23-1_002.jpg GRAPHIC 4490
11 GRAPHIC ex23-1_003.jpg GRAPHIC 5686
  Complete submission text file 0001213900-25-039303.txt   675798
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: F-3 | Act: 33 | File No.: 333-286956 | Film No.: 25909886
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)